PRINCETON, N.J., June 16 /PRNewswire/ -- Celator Pharmaceuticals today announced that John Bennett, head of business development, is scheduled to present at the BIO Business Forum during the Biotechnology Industry Organization (BIO) International Convention in San Diego. Mr. Bennett will provide a corporate overview and an update on Celator’s clinical development programs. The presentation will be held on Wednesday, June 18, 2008 at 3:30 PDT in Room 3 of the San Diego Convention Center.
About Celator
Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company’s drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company’s website at www.celatorpharma.com.
CONTACT: Sara LizzoBerry & Company Public Relations, +1-212-253-8881,
slizzo@berrypr.com
Web site: http://www.celatorpharma.com/
